Ignite Creation Date:
2024-05-06 @ 8:32 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02761694
Status:
TERMINATED
Last Update Posted:
2023-05-06
First Post:
2016-04-29
Brief Title:
Vevorisertib ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Solid Tumors With PIK3CA AKT PTEN Mutations MK-4440-001
Sponsor:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-10
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-29
First Submit QC Date:
May 3 2016
Study First Post Date:
2016-05-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2022-06-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-02
Last Update Post Date:
2023-05-06
Last Update Post Date Type:
ACTUAL